Total Payments
$33,653
2024 Payments
$831.00
Companies
15
Transactions
58
Medicare Patients
495
Medicare Billing
$147,448
Payment Breakdown by Category
Consulting$27,119 (80.6%)
Travel$3,728 (11.1%)
Other$1,750 (5.2%)
Food & Beverage$814.34 (2.4%)
Education$182.12 (0.5%)
Research$60.01 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $27,119 | 11 | 80.6% |
| Travel and Lodging | $3,728 | 14 | 11.1% |
| Honoraria | $1,750 | 1 | 5.2% |
| Food and Beverage | $814.34 | 20 | 2.4% |
| Education | $182.12 | 11 | 0.5% |
| Unspecified | $60.01 | 1 | 0.2% |
Payments by Type
General
$33,593
57 transactions
Research
$60.01
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $7,048 | 7 | $0 (2018) |
| Incyte Corporation | $6,730 | 12 | $0 (2019) |
| JAZZ PHARMACEUTICALS INC. | $6,689 | 9 | $0 (2019) |
| PFIZER INC. | $4,391 | 11 | $0 (2021) |
| Amgen Inc. | $4,147 | 3 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $2,904 | 4 | $0 (2023) |
| GENZYME CORPORATION | $831.00 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $525.00 | 1 | $0 (2023) |
| Celgene Corporation | $174.13 | 3 | $0 (2023) |
| Astellas Pharma Global Development | $60.01 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $831.00 | 1 | GENZYME CORPORATION ($831.00) |
| 2023 | $3,548 | 6 | E.R. Squibb & Sons, L.L.C. ($2,849) |
| 2022 | $35.84 | 1 | E.R. Squibb & Sons, L.L.C. ($35.84) |
| 2021 | $3,697 | 2 | Amgen Inc. ($1,947) |
| 2020 | $2,244 | 4 | Amgen Inc. ($2,200) |
| 2019 | $6,852 | 19 | JAZZ PHARMACEUTICALS INC. ($6,689) |
| 2018 | $9,577 | 10 | Daiichi Sankyo Inc. ($7,048) |
| 2017 | $6,867 | 15 | Incyte Corporation ($6,705) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/01/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $831.00 | General |
| Category: Oncology | ||||||
| 08/29/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $81.13 | General |
| 08/21/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,768.00 | General |
| 08/07/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 07/14/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $133.35 | General |
| 07/14/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 07/14/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $10.78 | General |
| 12/09/2022 | E.R. Squibb & Sons, L.L.C. | SPRYCEL (Drug) | Education | In-kind items and services | $35.84 | General |
| Category: Oncology | ||||||
| 09/16/2021 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,947.00 | General |
| 08/30/2021 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $1,750.00 | General |
| 11/11/2020 | Amgen Inc. | Blincyto (Biological) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 11/11/2020 | Amgen Inc. | Blincyto (Biological) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 10/27/2020 | E.R. Squibb & Sons, L.L.C. | INREBIC (Drug) | Education | Cash or cash equivalent | $19.42 | General |
| Category: Hematology | ||||||
| 01/24/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug), Nexavar, Vitrakvi | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Oncology | ||||||
| 12/06/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $60.01 | Research |
| Study: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation • Category: ONCOLOGY | ||||||
| 07/26/2019 | PFIZER INC. | DAURISMO (Drug) | Education | In-kind items and services | $10.70 | General |
| Category: ONCOLOGY | ||||||
| 05/28/2019 | JAZZ PHARMACEUTICALS INC. | — | Consulting Fee | Cash or cash equivalent | $530.00 | General |
| 05/07/2019 | JAZZ PHARMACEUTICALS INC. | — | Consulting Fee | Cash or cash equivalent | $4,770.00 | General |
| 04/27/2019 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | Cash or cash equivalent | $618.78 | General |
| 04/27/2019 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | Cash or cash equivalent | $247.80 | General |
| 04/27/2019 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | Cash or cash equivalent | $213.57 | General |
| 04/27/2019 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | Cash or cash equivalent | $169.00 | General |
| 04/27/2019 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | Cash or cash equivalent | $111.91 | General |
| 04/27/2019 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | Cash or cash equivalent | $24.00 | General |
| 04/27/2019 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | Cash or cash equivalent | $4.06 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation | Astellas Pharma Global Development | $60.01 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 123 | 414 | $198,293 | $41,588 |
| 2022 | 5 | 139 | 373 | $168,801 | $38,128 |
| 2021 | 4 | 113 | 338 | $155,155 | $35,590 |
| 2020 | 5 | 120 | 365 | $146,998 | $32,142 |
Total Patients
495
Total Services
1,490
Medicare Billing
$147,448
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 72 | 287 | $146,934 | $30,311 | 20.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 98 | $33,516 | $9,179 | 27.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 12 | $4,260 | $1,115 | 26.2% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 14 | 17 | $13,583 | $983.52 | 7.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 66 | 216 | $104,112 | $24,703 | 23.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 23 | 90 | $30,780 | $7,616 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 26 | 41 | $14,719 | $3,004 | 20.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 12 | $8,004 | $1,974 | 24.7% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 13 | 14 | $11,186 | $832.45 | 7.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 65 | 235 | $112,528 | $27,480 | 24.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 63 | $21,002 | $5,445 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 23 | $8,042 | $1,663 | 20.7% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 15 | 17 | $13,583 | $1,002 | 7.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 63 | 213 | $91,377 | $18,305 | 20.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 20 | 114 | $35,112 | $10,032 | 28.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 14 | 14 | $8,358 | $2,274 | 27.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 12 | 13 | $3,362 | $788.40 | 23.5% |
| 38222 | Bone marrow biopsy and aspiration | Facility | 2020 | 11 | 11 | $8,789 | $742.49 | 8.4% |
About Dr. Jan Cerny, M.D
Dr. Jan Cerny, M.D is a Internal Medicine healthcare provider based in Worcester, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407887771.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jan Cerny, M.D has received a total of $33,653 in payments from pharmaceutical and medical device companies, with $831.00 received in 2024. These payments were reported across 58 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($27,119).
As a Medicare-enrolled provider, Cerny has provided services to 495 Medicare beneficiaries, totaling 1,490 services with total Medicare billing of $147,448. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Worcester, MA
- Active Since 07/05/2006
- Last Updated 11/03/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1407887771
Products in Payments
- JAKAFI (Drug) $6,730
- Blincyto (Biological) $2,200
- SARCLISA (Biological) $831.00
- CALQUENCE (Drug) $525.00
- BESPONSA (Drug) $67.95
- XOSPATA (Drug) $60.01
- SPRYCEL (Drug) $55.19
- ADCETRIS (Biological) $54.00
- GILOTRIF (Drug) $39.92
- MYLOTARG (Biological) $30.00
- Stivarga (Drug) $24.98
- BESPONSA (Biological) $24.04
- INREBIC (Drug) $19.42
- NINLARO (Drug) $15.55
- DAURISMO (Drug) $10.70
- BOSULIF (Drug) $8.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Worcester
Jonathan Kay, Md, MD
Internal Medicine — Payments: $341,486
Internal Medicine $341,486
Leslie Harrold, M.d, M.D
Internal Medicine — Payments: $81,558
Internal Medicine $81,558
Bogdan Nedelescu, M.d, M.D
Internal Medicine — Payments: $50,128
Internal Medicine $50,128
Nikhil Shah, M.d, M.D
Internal Medicine — Payments: $39,924
Internal Medicine $39,924
Dr. Deepa Jagadeesh, M.d, M.D
Internal Medicine — Payments: $37,078
Internal Medicine $37,078
Dr. Julia Andrieni, M.d, M.D
Internal Medicine — Payments: $35,880
Internal Medicine $35,880